The impact of donor‐specific anti‐HLA antibody levels on primary poor graft function and graft rejection in rituximab desensitized haploidentical stem cell transplantation

Jing Liu,Xiang‐Yu Zhao,Lan‐Ping Xu,Xiao‐Hui Zhang,Yu Wang,Xiao‐Dong Mo,Yuan‐Yuan Zhang,Xiao‐Su Zhao,Yi‐Fei Cheng,Kai‐Yan Liu,Xiao‐Jun Huang,Ying‐Jun Chang
DOI: https://doi.org/10.1111/tan.15300
2023-11-22
HLA
Abstract:This study investigates the influence of donor‐specific anti‐HLA antibodies (DSA) levels on primary poor graft function (PGF) and graft rejection (GR) after haploidentical stem cell transplantation (haplo‐SCT) with rituximab desensitization. A total of 155 DSA‐positive haplo‐SCT candidates with mean fluorescence intensity (MFI) between 2000 and 10,000 were enrolled in this prospective clinical trial. Receiver operating characteristic (ROC) curves determined the optimal DSA MFI cutoff for identifying high‐risk patients. Patients were categorized into two groups: DSA low‐level group (2000 ≤ DSA MFI
pathology,immunology,cell biology
What problem does this paper attempt to address?